- Home
- BSLK vs NERV Comparison
BSLK vs NERV Comparison
Compare BSLK & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSLK
- NERV
- Stock Information
- Founded
- BSLK 2009
- NERV 2007
- Country
- BSLK United States
- NERV United States
- Employees
- BSLK N/A
- NERV N/A
- Industry
- BSLK
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- BSLK
- NERV Health Care
- Exchange
- BSLK NYSE
- NERV Nasdaq
- Market Cap
- BSLK 12.3M
- NERV 10.7M
- IPO Year
- BSLK N/A
- NERV 2014
- Fundamental
- Price
- BSLK $0.31
- NERV $1.61
- Analyst Decision
- BSLK
- NERV Hold
- Analyst Count
- BSLK 0
- NERV 1
- Target Price
- BSLK N/A
- NERV $5.00
- AVG Volume (30 Days)
- BSLK 197.5K
- NERV 15.1K
- Earning Date
- BSLK 05-21-2025
- NERV 04-30-2025
- Dividend Yield
- BSLK N/A
- NERV N/A
- EPS Growth
- BSLK N/A
- NERV N/A
- EPS
- BSLK N/A
- NERV 0.19
- Revenue
- BSLK $1,373,000.00
- NERV N/A
- Revenue This Year
- BSLK N/A
- NERV N/A
- Revenue Next Year
- BSLK N/A
- NERV N/A
- P/E Ratio
- BSLK N/A
- NERV $8.95
- Revenue Growth
- BSLK N/A
- NERV N/A
- 52 Week Low
- BSLK $0.23
- NERV $1.42
- 52 Week High
- BSLK $17.02
- NERV $3.69
- Technical
- Relative Strength Index (RSI)
- BSLK N/A
- NERV 41.00
- Support Level
- BSLK N/A
- NERV $1.54
- Resistance Level
- BSLK N/A
- NERV $1.89
- Average True Range (ATR)
- BSLK 0.00
- NERV 0.11
- MACD
- BSLK 0.00
- NERV 0.00
- Stochastic Oscillator
- BSLK 0.00
- NERV 22.68
About BSLK BOLT PROJECTS HOLDINGS INC
Bolt Projects Holdings Inc formerly Golden Arrow Merger Corp is an shell company.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.